ubiquitinproteasom
system
up
pervad
biolog
eukaryot
depend
activ
hundr
differ
enzym
proteinprotein
interact
up
provid
mani
opportun
select
modul
pathway
small
molecul
discuss
principl
underli
develop
effect
inhibitor
activ
pathway
emphas
insight
structur
analysi
describ
strategi
evalu
select
compound
sculpt
proteom
small
molecul
ubiquitinproteasom
system
up
pervad
biolog
eukaryot
depend
activ
hundr
differ
enzym
proteinprotein
interact
up
provid
mani
opportun
select
modul
pathway
small
molecul
discuss
principl
underli
develop
effect
inhibitor
activ
pathway
emphas
insight
structur
analysi
describ
strategi
evalu
select
compound
system
surpris
complex
specif
evolv
control
stabil
protein
cell
select
tag
protein
ubiquitin
enzym
up
reduc
halflif
protein
month
minut
tag
process
requir
trio
differ
protein
class
call
sequenti
activ
ubiquitin
attach
substrat
degrad
proteasom
requir
protein
tag
multipl
ubiquitin
molecul
gener
form
ubiquitin
chain
proteas
remov
ubiquitin
substrat
call
deubiquitin
enzym
dub
modul
degrad
addit
protein
act
receptor
ubiquitin
ubiquitinlik
protein
altogeth
protein
may
function
up
yield
vast
playground
exploratori
chemic
biolog
drug
develop
describ
challeng
success
develop
select
compound
modul
up
comprehens
descript
compound
room
discuss
refer
reader
ref
enzym
ubiquitin
pathway
catalyz
format
isopeptid
bond
c
terminu
ubiquitin
eamino
group
lysin
residu
substrat
protein
includ
ubiquitin
case
ubiquitin
chain
format
isopeptid
bond
format
occur
least
three
distinct
step
first
c
terminu
ubiquitin
activ
reaction
use
atp
proce
format
ubiquitinadenyl
intermedi
subsequ
transfer
cystein
form
thioester
next
charg
highenergi
form
ubiquitin
transfer
cystein
final
step
ubiquitin
transfer
substrat
lysin
assist
ring
domaincontain
bring
substrat
close
proxim
also
enhanc
abil
transfer
ubiquitin
substrat
altern
pathway
hect
rbr
class
accept
ubiquitin
form
thioester
transfer
substrat
cystein
chemistri
also
predomin
ubiquitin
remov
dub
thiolcontain
proteas
use
activ
site
cystein
hydrolyz
isopeptid
bond
fact
dub
enzym
creat
opportun
modul
activ
small
molecul
bind
near
activ
site
howev
involv
reactiv
cystein
enzym
creat
challeng
develop
select
inhibitor
electrophil
compound
may
react
nonspecif
cystein
mani
report
inhibitor
dub
contain
electrophil
thu
compound
tend
limit
specif
decreas
use
tool
compound
hinder
develop
drug
select
inhibitor
enzym
develop
guard
possibl
inhibitor
nonselect
modifi
thiol
one
answer
perform
extens
vitro
profil
screen
hit
thiolcontain
enzym
pathway
approach
perform
use
assay
measur
individu
biochem
function
purifi
enzym
manner
analog
profil
atpcompetit
kinas
inhibitor
panel
kinas
use
newli
develop
proteom
method
furthermor
demonstr
revers
inhibit
import
rule
compound
react
activ
site
addit
propos
test
whether
compound
induc
could
help
flag
reactiv
compound
transcript
factor
induc
express
antioxid
gene
level
regul
call
unperturb
cell
promot
ubiquityl
keep
level
low
howev
oxid
electrophil
present
inactiv
caus
accumul
activ
express
target
mani
cystein
residu
vari
reactiv
profil
make
sensit
wide
rang
xenobiot
electrophil
reactiv
cystein
dispers
function
domain
modif
may
inhibit
differ
mechan
detect
wide
rang
electrophil
report
assay
may
simpl
counterscreen
detect
reactiv
compound
enzym
class
small
two
activ
ubiquitin
wherea
member
class
activ
ubl
protein
relat
ubiquitin
one
ubl
call
dynam
modifi
larg
class
enzym
cullinr
ligas
turn
activ
cullinr
ligas
regul
cell
prolifer
nae
emerg
possibl
target
cancer
treatment
millennium
develop
remark
inhibitor
reactiv
analog
npg
commentari
amp
intercept
normal
pathway
activ
normal
nae
bind
atp
creat
intermedi
attack
activ
site
cystein
form
thioester
fig
presenc
howev
thioester
attack
reactiv
element
amp
analog
form
coval
intermedi
remain
tightli
noncoval
bound
enzym
block
function
fig
c
draw
kinas
inhibitor
field
subtl
modif
purin
ribos
element
inhibitor
made
select
nae
rel
ubiquitin
principl
possibl
use
strategi
develop
select
inhibitor
activ
ubiquitin
entir
set
ubl
protein
remark
featur
inhibitor
compon
inhibitori
speci
incorpor
inhibitor
extend
contact
area
nae
thu
exhibit
low
offrat
fig
enzym
class
compris
member
function
togeth
subset
although
yet
precis
map
relationship
typic
govern
topolog
ubiquitin
chain
construct
ring
ligas
exampl
elong
ubiquitin
chain
link
ubiquitin
select
inhibitor
discov
biochem
screen
inhibitor
ubiquitin
ref
screen
panel
suggest
effect
specif
compar
surprisingli
biochem
studi
show
coval
inactiv
block
abil
accept
ubiquitin
instead
compound
slow
discharg
ubiquitin
bind
composit
interfac
form
residu
ubiquitin
fig
thu
much
higher
affin
complex
rel
free
enzym
bind
interfac
compound
impair
abil
enzym
transfer
ubiquitin
substrat
presenc
make
contact
residu
conserv
explain
specif
open
question
includ
whether
possibl
use
strategi
develop
highli
potent
compound
use
drug
whether
select
inhibitor
obtain
exploit
similar
principl
dub
famili
consist
enzym
major
thiol
proteas
mani
report
inhibitor
thiol
proteas
select
may
inactiv
enzym
target
coval
even
inhibitor
appear
revers
select
yet
understand
basi
select
structur
perspect
one
except
inhibit
papainlik
proteas
plpro
requir
cleavag
viral
polyprotein
coronaviru
caus
sever
acut
respiratori
syndrom
proteas
also
cleav
ubiquitin
structur
homolog
dub
usp
famili
lead
compound
discov
highthroughput
screen
follow
medicin
chemistri
optim
yield
inhibit
enzym
halfmaximum
inhibitori
concentr
nm
structur
analysi
indic
compound
bind
away
catalyt
cystein
subsit
enzym
normal
receiv
ctermin
tail
ubiquitin
fig
bind
inhibitor
stabil
closur
loop
would
otherwis
wrap
around
ubiquitin
tail
structur
align
plpro
close
relat
enzym
indic
two
residu
steric
clash
bind
site
explain
inhibitor
specif
plpro
rel
residu
found
usp
suggest
unlik
inhibit
enzym
either
inhibitor
dub
show
evid
select
revers
case
lack
structur
insight
explain
mechan
select
inhibitor
proteasomeassoci
dub
ref
inhibitor
revers
show
littl
activ
dub
select
rel
highli
relat
enzym
recent
new
deriv
develop
show
nanomolar
potenc
retain
select
unpublish
data
cell
acceler
degrad
subset
up
substrat
includ
tau
antagon
proteasomedepend
deubiquitin
effect
lost
cell
lack
indic
effect
mediat
inhibit
strongli
activ
bind
proteasom
inhibit
activ
form
enzym
although
hamper
structur
analysi
interact
suggest
bind
site
form
enzym
activ
recent
revers
potent
inhibitor
report
inhibit
k
less
nm
highli
select
determin
vitro
assay
dub
profil
cell
hydrogendeuterium
exchang
experi
suggest
compound
bind
outsid
activ
site
predict
known
role
dna
repair
sensit
cell
effect
dna
damag
agent
compromis
dna
repair
pathway
function
critic
caus
addit
sensit
cell
knock
indic
effect
ontarget
recent
studi
suggest
dub
inhibitor
may
therapeut
potenti
select
inhibitor
found
activ
anim
model
multipl
myeloma
suggest
target
dub
may
effect
approach
cancer
inhibitor
also
highlight
counterintuit
principl
dub
inhibitor
block
proteolysi
up
substrat
albeit
indirectli
effect
origin
capac
mani
undergo
autoubiquitin
case
antagon
ubiquitin
autoubiquityl
lead
destruct
inhibitor
promot
degrad
turn
stabil
substrat
particularli
stabil
compound
may
use
treatment
certain
cancer
anoth
exampl
posit
regul
ligas
dub
provid
recent
work
enzym
duba
induc
substrat
select
up
typic
mediat
abil
recogn
specif
sequenc
motif
substrat
protein
furthermor
regul
proteolysi
often
govern
posttransl
modif
substrat
may
either
block
promot
substrat
recognit
case
activ
regul
posttransl
modif
inhibitor
enzym
carri
modif
protein
kinas
inhibitor
thu
modul
protein
stabil
number
small
molecul
identifi
modul
abil
recogn
substrat
direct
way
well
interest
exampl
discov
plant
auxin
canon
plant
hormon
work
govern
morphogenesi
growth
process
hormon
effect
auxin
achiev
target
famili
transcript
repressor
ubiquitindepend
destruct
absenc
auxin
substrat
effici
recogn
requir
portion
substrat
bind
pocket
absent
auxin
bind
complet
pocket
engag
direct
contact
substrat
fig
recent
work
suggest
similar
principl
exploit
drug
develop
thalidomid
discov
serendipit
effect
multipl
myeloma
mechan
action
remain
unclear
decad
biochem
studi
reveal
thalidomid
interact
call
cereblon
may
antagon
degrad
substrat
lenalidomid
identifi
potent
effect
version
thalidomid
also
bind
cereblon
surprisingli
found
inhibit
promot
degrad
two
transcript
factor
essenti
viabil
myeloma
cell
structur
studi
indic
lenalidomid
dock
within
caviti
presum
locat
substrat
bind
pocket
portion
lenalidomid
project
caviti
may
promot
new
bind
interact
substrat
manner
markedli
analog
auxin
fig
g
appear
endogen
small
molecul
may
regul
ubiquitindepend
destruct
substrat
well
mammal
key
element
circadian
clock
cryptochrom
cri
transcript
repressor
undergo
diurnal
cycl
synthesi
degrad
cri
flavoprotein
exchang
cofactor
fad
compet
ubiquitin
ligas
cri
bind
thu
presenc
endogen
compound
act
antagonist
degrad
protein
essenti
opposit
happen
auxin
interest
futur
question
whether
endogen
metabolit
human
cell
also
regul
protein
stabil
either
promot
inhibit
recognit
substrat
mani
recogn
substrat
short
sequenc
motif
small
molecul
identifi
inhibitor
activ
often
prove
block
interact
exampl
potent
compound
develop
block
interact
abovement
ref
tool
compound
identifi
block
substrat
recognit
well
recent
found
use
combin
small
molecul
target
substrat
recognit
activ
protein
bind
effect
inactiv
larg
multisubunit
anaphasepromot
complex
compound
synergist
inhibit
anaphasepromot
complex
function
substrat
promot
cooper
bind
activ
final
strategi
exploit
inhibit
ubiquitin
ligas
stimul
abil
ubiquityl
seen
inher
mani
absenc
substrat
bind
call
xiap
inhibit
activ
intramolecular
interact
upon
disrupt
interact
small
molecul
dimer
becom
activ
absenc
substrat
tend
ubiquityl
rather
substrat
result
ubiquitindepend
destruct
xiap
interest
determin
whether
featur
regul
exploit
inhibit
futur
exampl
illustr
potenti
develop
specif
potent
molecul
modul
activ
up
develop
gener
rule
regard
best
approach
identif
select
compound
difficult
howev
dub
repres
differ
class
enzym
even
dub
alon
repres
five
distinct
enzym
class
nonetheless
interest
theme
emerg
analysi
exampl
first
possibl
exploit
interact
ubiquitin
target
enzym
develop
select
inhibitor
illustr
inhibitor
inhibitor
recent
proofofprincipl
experi
suggest
might
possibl
exploit
similar
strategi
inhibit
dub
possibl
identifi
mutant
ubiquitin
bind
specif
dub
high
affin
inhibit
activ
perhap
possibl
mimic
effect
identifi
small
molecul
stabil
bind
ubiquitin
dub
manner
analog
effect
discoveri
effort
date
point
hazard
relat
identifi
reactiv
compound
vitro
biochem
screen
inhibitor
dub
addit
biochem
profil
assay
new
proteom
techniqu
take
advantag
reactiv
ubiquitin
probe
make
possibl
profil
select
inhibitor
mani
dub
express
cell
anoth
effect
approach
establish
specif
compound
determin
whether
genet
ablat
enzym
abrog
physiolog
effect
inhibitor
approach
use
success
sever
case
appli
whenev
enzym
requir
viabil
cell
structur
analysi
compound
bound
target
given
us
uniqu
insight
differ
small
molecul
modul
interest
lesson
auxin
thalidomid
lenalidomid
exampl
one
may
readili
turn
inhibitor
activ
activ
inhibitor
subtl
chang
chemic
structur
ligand
exampl
inhibitor
auxin
system
auxinol
develop
antagon
substrat
bind
rather
promot
similarli
thalidomid
thought
antagon
bind
physiolog
cereblon
substrat
wherea
lenalidomid
promot
bind
appear
neosubstr
small
chang
molecular
structur
affect
bind
substrat
fascin
problem
futur
work
chemic
biolog
although
larg
number
dub
inhibitor
describ
specif
util
vari
great
deal
structur
understand
dub
inhibitor
bind
inactiv
target
poorli
develop
constitut
major
limit
field
case
also
limit
understand
relev
substrat
dub
thu
remain
difficult
predict
biolog
impact
dub
inhibit
dub
inhibitor
may
stimul
degrad
substrat
directli
inhibit
deubiquitin
discuss
may
block
degrad
substrat
indirectli
promot
degrad
up
strike
breadth
complex
though
understand
gener
featur
pathway
gain
insight
physiolog
function
number
wellstudi
exampl
surpris
still
emerg
regular
basi
fact
vast
major
function
term
physiolog
role
substrat
specif
remain
unstudi
clinic
util
thalidomid
subsequ
lenalidomid
discov
empir
molecular
mechan
understood
similarli
arsen
trioxid
retino
acid
approv
promyelocyt
leukemia
well
understood
modifi
essenti
oncoprotein
make
suscept
destruct
up
proteasom
inhibitor
develop
initi
combat
muscl
wast
specif
toxic
myeloma
cell
discov
serendipit
use
cellbas
screen
thu
prejudg
best
discov
use
drug
chemic
tool
like
emerg
varieti
approach
year
come
